Stockholders' Equity (Details Textual) - USD ($)
|
|
|
|
|
|
|
|
1 Months Ended |
12 Months Ended |
|
|
|
Jan. 01, 2019 |
Mar. 13, 2018 |
Mar. 12, 2018 |
Aug. 03, 2017 |
Apr. 07, 2017 |
Mar. 13, 2017 |
Mar. 13, 2016 |
Jan. 31, 2019 |
Jun. 30, 2018 |
Aug. 31, 2017 |
Apr. 24, 2017 |
Mar. 31, 2017 |
Feb. 28, 2017 |
Jan. 31, 2017 |
Oct. 31, 2016 |
Dec. 31, 2018 |
Dec. 31, 2017 |
Dec. 31, 2016 |
Jul. 31, 2018 |
Dec. 12, 2016 |
Jul. 31, 2016 |
| Share-based Compensation Arrangement by Share-based Payment Award [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common Stock, Shares, Issued |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
26,610,183
|
25,236,255
|
|
|
|
|
| Common Stock, Shares Authorized |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
50,000,000
|
50,000,000
|
|
|
|
|
| Common Stock, Par or Stated Value Per Share |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 0.0001
|
$ 0.0001
|
|
|
|
|
| Common Stock, Voting Rights |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1.1
|
|
|
|
|
|
| Warrants Issued |
|
|
|
|
|
|
|
|
|
|
|
16,000
|
|
2,134,193
|
|
|
|
|
|
|
|
| Allocated Share-based Compensation Expense |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 34,000
|
$ 10,000
|
|
|
|
|
| Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
5,500,000
|
|
|
|
|
|
| Common Stock, Shares Subscribed but Unissued |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
709,314
|
834,756
|
|
|
|
|
| Common Stock, Value, Subscriptions |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 2,085,000
|
$ 9,558,000
|
|
|
|
|
| Shares Issued, Price Per Share |
|
|
$ 11.45
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Payments of Stock Issuance Costs |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 0
|
$ 5,674,000
|
|
|
|
|
| Preferred Stock, Shares Authorized |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2,000,000
|
2,000,000
|
|
|
|
|
| Stock Issued During Period, Value, Issued for Services |
|
|
|
|
|
|
|
|
|
|
|
|
$ 1,700,000
|
|
|
|
|
|
|
|
|
| Proceeds from Issuance of Private Placement |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 10,000,000
|
|
|
|
|
|
|
| Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The remaining 50% (the “Performance Options”) vest and become exercisable upon the occurrence of the following milestones being achieved: (i) 25% of the Performance Options vest upon the dosing of the first patient in the first Phase 2 clinical trial of any Company product candidate, (ii) 25% of the Performance Options vest upon the dosing of the first patient in the first Phase 2 clinical trial of a second Company product candidate, (iii) 25% of the Performance Options vest upon the Company’s achievement of a fully-diluted market capitalization of $500,000,000 and (iv) 25% of the Performance Options vest upon the Company’s achievement of a fully-diluted market capitalization of $1,000,000,000.
|
|
|
|
|
|
| Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 5.73
|
|
|
|
|
|
| Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0.00%
|
|
|
|
|
|
| Research and Development Expense |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 2,100,000
|
|
|
|
|
|
| Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2,049,689
|
|
|
|
|
|
| Maximum Value Of Shares Authorized |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 75,000,000
|
|
|
| Commission Rate Percentage |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3.00%
|
|
|
| Preferred Stock, Dividend Rate, Percentage |
|
|
|
|
|
|
|
2.00%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Maximum [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Share-based Compensation Arrangement by Share-based Payment Award [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized |
|
|
|
|
|
|
|
|
5,000,000
|
|
|
|
|
|
|
|
|
|
|
|
|
| Minimum [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Share-based Compensation Arrangement by Share-based Payment Award [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized |
|
|
|
|
|
|
|
|
3,000,000
|
|
|
|
|
|
|
|
|
|
|
|
|
| Incentive Plan 2016 [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Share-based Compensation Arrangement by Share-based Payment Award [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10 years
|
|
|
|
|
|
| Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2,000,000
|
|
|
|
|
|
| Restricted Stock [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Share-based Compensation Arrangement by Share-based Payment Award [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Allocated Share-based Compensation Expense |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 1,900,000
|
|
|
|
|
|
| Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
322,636
|
180,000
|
|
|
|
|
| Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2 years 6 months
|
|
|
|
|
|
| Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 5.78
|
$ 5.73
|
|
|
|
|
| Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
68,158
|
|
|
|
|
|
| Restricted Stock Units (RSUs) [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Share-based Compensation Arrangement by Share-based Payment Award [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Allocated Share-based Compensation Expense |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 4,200,000
|
|
|
|
|
|
| Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1,072,000
|
134,000
|
|
|
|
|
| Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2 years 2 months 12 days
|
|
|
|
|
|
| Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 8.16
|
$ 6.53
|
|
|
|
|
| Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
230,000
|
|
|
|
|
|
| Employee Stock Option [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Share-based Compensation Arrangement by Share-based Payment Award [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Stock Repurchased During Period, Shares |
|
|
|
|
|
|
|
|
|
|
1,041,675
|
|
|
|
|
|
|
|
|
|
|
| Allocated Share-based Compensation Expense |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 1,100,000
|
|
|
|
|
|
| Shares Issued, Price Per Share |
|
|
|
|
$ 5.73
|
|
|
|
|
|
$ 5.73
|
|
|
|
|
|
|
|
|
|
|
| Stock Issued During Period, Shares, Issued for Services |
|
|
|
|
200,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2 years
|
|
|
|
|
|
| Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeiture Rate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0.00%
|
|
|
|
|
| Employee Stock Option [Member] | Restricted Stock [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Share-based Compensation Arrangement by Share-based Payment Award [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 5.73
|
|
|
|
|
|
| General and Administrative Expense [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Share-based Compensation Arrangement by Share-based Payment Award [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Allocated Share-based Compensation Expense |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 1,200,000
|
|
|
|
|
|
| Common Stock [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Share-based Compensation Arrangement by Share-based Payment Award [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Preferred Stock, Shares Authorized |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
5,000,000
|
2,000,000
|
|
|
|
|
| Unregistered Common Stock [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Share-based Compensation Arrangement by Share-based Payment Award [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Stock Issued During Period, Shares, New Issues |
|
|
|
|
|
|
|
|
|
|
|
64,000
|
|
8,536,774
|
|
|
|
|
|
|
|
| Common Class B [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Share-based Compensation Arrangement by Share-based Payment Award [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common Stock, Shares Authorized |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
15,000,000
|
| Common Class A [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Share-based Compensation Arrangement by Share-based Payment Award [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common Stock, Shares, Issued |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1,000,000
|
1,000,000
|
|
|
|
|
| Common Stock, Shares Authorized |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1,000,000
|
|
|
|
| Fortress Biotech, Inc [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Share-based Compensation Arrangement by Share-based Payment Award [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common Stock, Shares, Issued |
|
|
834,756
|
|
|
|
|
|
|
365,639
|
|
|
|
|
|
|
|
|
|
|
|
| Common Stock, Value, Subscriptions |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 900,000
|
|
| Shares Issued, Price Per Share |
|
|
|
|
|
$ 5.73
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Stock Issued During Period, Shares, Issued for Services |
709,314
|
|
|
|
|
767,264
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Stock Issued During Period, Value, Issued for Services |
|
|
|
|
|
$ 4,400,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Research and Development Expense |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 9,600,000
|
|
|
|
|
| Common Stock, Capital Shares Reserved for Future Issuance |
|
834,756
|
834,756
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Preferred Stock, Dividend Rate, Percentage |
2.00%
|
2.50%
|
2.50%
|
|
|
|
|
|
|
2.50%
|
|
|
|
|
|
|
|
|
|
|
|
| Fortress Biotech, Inc [Member] | Common Stock [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Share-based Compensation Arrangement by Share-based Payment Award [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Shares Of Common Stock, Percentage |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2.50%
|
|
|
|
|
|
| Stock Issued During Period, Shares, New Issues |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
982,533
|
|
|
|
|
|
| Common Stock, Shares Subscribed but Unissued |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2,000,000
|
|
|
|
| Research and Development Expense |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 9,600,000
|
|
|
|
|
| Fortress Biotech, Inc [Member] | Common Class B [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Share-based Compensation Arrangement by Share-based Payment Award [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common Stock, Shares, Issued |
|
|
|
|
|
|
250,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common Stock, Shares Subscribed but Unissued |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
7,000,000
|
|
|
|
| Diluted Outstanding Equity, Percentage |
|
|
|
|
|
|
2.50%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Fortress Biotech, Inc [Member] | Common Stock B Two [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Share-based Compensation Arrangement by Share-based Payment Award [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common Stock, Shares, Issued |
|
|
|
|
|
767,264
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Research and Development Expense |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 4,400,000
|
|
|
|
| Preferred Stock, Dividend Rate, Percentage |
|
|
|
|
|
2.50%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| National Holdings Corporation [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Share-based Compensation Arrangement by Share-based Payment Award [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Warrants Issued |
|
|
|
2,500
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| National Holdings Corporation [Member] | Unregistered Common Stock [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Share-based Compensation Arrangement by Share-based Payment Award [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Stock Issued During Period, Shares, New Issues |
|
|
|
10,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| City of Hope National Medical Center [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Share-based Compensation Arrangement by Share-based Payment Award [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Stock Issued During Period, Shares, New Issues |
|
|
|
|
|
|
|
|
|
|
|
|
293,588
|
|
|
|
|
|
|
|
|
| City of Hope National Medical Center [Member] | Common Stock [Member] | Original Agreement [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Share-based Compensation Arrangement by Share-based Payment Award [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Shares, Issued |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
293,588
|
|
|
|
|
|
| City of Hope National Medical Center [Member] | Common Class A [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Share-based Compensation Arrangement by Share-based Payment Award [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Shares, Issued |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1,000,000
|
|
|
|
|
|
| National Securities, Inc [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Share-based Compensation Arrangement by Share-based Payment Award [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Percentage Of Shares Issued To Placement Agent |
|
|
|
10.00%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Warrants Issued |
|
|
|
1,000
|
|
|
|
|
|
|
|
6,400
|
|
853,677
|
|
|
|
|
|
|
|
| Private Placement [Member] | National Holdings Corporation [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Share-based Compensation Arrangement by Share-based Payment Award [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Percentage Of Placement Agent Fee |
|
|
|
|
|
|
|
|
|
|
|
10.00%
|
|
10.00%
|
|
|
|
|
|
|
|
| Percentage Of Shares Issued To Placement Agent |
|
|
|
|
|
|
|
|
|
|
|
10.00%
|
|
10.00%
|
|
|
|
|
|
|
|
| Payments of Stock Issuance Costs |
|
|
|
|
|
|
|
|
|
|
|
$ 42,000
|
|
$ 5,500,000
|
|
|
|
|
|
|
|
| Proceeds from Issuance of Private Placement |
|
|
|
$ 65,000
|
|
|
|
|
|
|
|
$ 400,000
|
|
$ 55,500,000
|
|
|
|
|
|
|
|